The End of Humira’s $200 Billion Drug Monopoly
Podcast |
Tradeoffs
Publisher |
Tradeoffs
Media Type |
audio
Categories Via RSS |
News
News & Politics
Science
Publication Date |
Jan 26, 2023
Episode Duration |
00:20:33

After 20 years, Humira – the best selling drug of all time – is finally facing direct competition. Typically, once generic drugs arrive on a market they dominate sales and deliver big savings. But Humira’s competitors, known as biosimilars, aren’t like most other generics.

This week, what makes this prescription drug showdown so unusual – and so important.

Guest:

Marta Wosińska, PhD, Visiting Fellow, Brookings Institution

Learn more and read a full transcript on our website.

Want more Tradeoffs? Sign up for our free manage.com/subscribe?u=6ab1fc39a0b1b15521551487c&id=89c5edcb93&utm_source=twitter-newsletter-signup&utm_medium=twitter">weekly newsletter featuring the latest health policy research and news.

Support this type of journalism today, with a gift.


Hosted on Acast. See acast.com/privacy for more information.

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review